Navigation Links
Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
Date:8/28/2008

VEDBAEK, Denmark, August 28 /PRNewswire-FirstCall/ -- Strong organic growth continued in Q2 2008 supported by new research product offerings. The development of Exiqon's first molecular diagnostic product based on miRNA profiling remains on track for year end launch.

- Revenue in Q2 2008 increased by 139% on the year-earlier period to DKK

28 million, totaling DKK 44.5 million in the first six months of 2008.

- Product sales in Q2 2008 increased by 239% on the same period last year

to DKK 26.3 million (including research product sales and diagnostic

sales) totaling DKK 40.5 million in the first six months of 2008.

Research product sales grew organically by 70% compared to Q2 2007.

- Direct contribution margin in Q2 2008 was 65% compared to 78% in the

same period last year, totaling 66% in the first six months of 2008.

Gross margin was 25% compared to 64% in the same period last year,

totaling 33% in the first six months of 2008. The gross margin was

affected by new product offerings and cost of unused capacity during the

current build-up phase.

- Total operating expenses in Q2 2008 increased by 80% on the same period

last year to DKK 48.3 million, totaling DKK 82.7 million in the first six

months of 2008. The increase in operating expenses is primarily due to

the acquisition of Oncotech Inc.

- Net loss for Q2 2008 was DKK 38.8, totaling DKK 63.5 million the first

six months of 2008. EPS amounted to DKK -1.37 in Q2 2008 and DKK -2.25 in

the first six months of 2008.

- Based on current activities, the financial guidance for 2008

is retained with revenue of DKK 140-150 million in 2008 including both

research product sales and diagnostic sales. A net loss of DKK 100-115

million is expected, for the full year 2008, including the effect of

costs of current incentive plans in the amount to DKK 6 million.

L
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. Exiqon: Major Shareholder Announcement
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. LPBP Inc. - Re-filing certification of interim filings
7. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
10. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... 2015 Immunocore Limited, a ... treat cancer, viral infections and autoimmune disease, today ... Bell , the Regius Professor of Medicine at ... the Strategic Coordination of Health Research, to its ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
(Date:3/27/2015)... März 2015  Peter Walter wurde als ... für seine bahnbrechende Arbeit ausgewählt, die sich ... werden, sowie für die Entschlüsselung der Komponenten ... Stress nutzen, der mit der Ansammlung von ... für Biochemie an der University of California, ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... applicator, ATLANTA, Sept. 22 CryoLife, Inc. ... tissue processing company, announced,today that it has begun ... Hemostase MPH to control bleeding in general, cardiac ... in the U. S., the United,Kingdom and Germany ...
... WILMINGTON, Del., Sept. 22 For,his lifetime commitment in ... and other environmental exposures on the developing fetus and ... Robert,L. Brent, MD, PhD, will be honored as the ... Excellence in Children,s Health Care by Nemours,one of the ...
... and Preclinical Research at Upcoming Conferences, CALGARY, ... NASDAQ: ONCY) today announced the participation of five ... four conferences,through November 15, 2008 covering clinical trial ... important time for Oncolytics as we begin to ...
Cached Biology Technology:CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc. 2CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc. 3Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Children's Health Care 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 3
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... research has uncovered an underutilized berry that could be the ... the Journal of Food Science , published by the ... amounts of lycopene and a related acidic compound, methyl-lycopenoate, which ... The bright red fruit has a tart flavor, and has ...
... world of the potential dangers of nuclear disposal and unforeseen ... detect the radioactive materials uranium and plutonium in waste water. ... appears in ACS, The Journal of Physical Chemistry C ... that it is highly likely that radioactive uranium and plutonium ...
... This news release is available in ... us have mixed feelings when remembering painful lessons in German or ... rules and patterns: using them correctly makes the difference between something ... at the University of Vienna have shown that sensitivity to very ...
Cached Biology News:Monkeys 'understand' rules underlying language musicality 2
... α-Amylase is a hydrolytic enzyme ... a mixture of glucose, maltose, maltotriose ... various fluids of the human,body are ... microbial,a-amylases are important enzymes for industry.4, ...
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
... Thermo Forma's stainless steel ... patented adjustable mechanism that ... different shaking angles, and ... placement.This universal rack holder ...
Biology Products: